Ranibizumab FDA Link

A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.

Also Known As:

Lucentis; RhuFab V2; V2, RhuFab

Amino Acids, Peptides, and Proteins: 1
- Proteins: 496323
  - Blood Proteins: 12679
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        Ranibizumab: 3343
    - Immunoproteins: 43
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        Ranibizumab: 3343
  - Globulins: 3119
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        Ranibizumab: 3343

Arslan Tsai Selected Research

Arslan Tsai Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure